05 Jan FarmaMondo appointed by Adienne to Manage Access for Thiotepa (Tepadina®)
FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by ADIENNE to distribute Tepadina® via a Managed Access Program for targeted Healthcare Providers in selected global territories.
Tepadina ®, an alkylating agent used with other medicines in the conditioning regimen before hematopoietic stem cell transplantation, is ADIENNE’s currently marketed product commercialized in 42 countries.
Since its approval in the EU in 2010, Tepadina ®, for which ODD has been granted in the European Union, U.S. and Switzerland, has attained a key role in many conditioning regimens before autologous and allogeneic HSCT for treating myeloma, lymphomas, acute leukemia and other malignant and non-malignant hematological diseases as well as for the treatment of solid tumors.
Program Contact details
For all inquiries regarding Tepadina®, please
contact FarmaMondo Program Manager, Tepadina®, Global Access. email@example.com, Phone: +41 91 6976392
FarmaMondo is a Swiss-based pharmaceutical company with a focus on providing paid access to unlicensed medicines. Our global footprint includes commercial operations in more than 70 markets, headquartered from Switzerland with regional hubs in Europe, Asia and Latin America.
ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs. ADIENNE aims to develop a range of product candidates for orphan diseases for which existing treatment options are limited, the patient population is small and the clinical needs for therapies is high.